ReviewCureus2026

Evaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence.

Brij Teli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.